Pharmaceuticals, Biotechnology and Life Sciences
Boston-based pharmaceutical company Rhythm has secured $41 million through mezzanine financing round to funds its melanocortin-4 receptor for the phase 3 study.
The U.S. Food and Drug Administration (FDA) has approved Valeant Pharmaceuticals’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis.
Denovo Biopharma’s new clinical center in China opened last year will play a very important role in the biomarker driven DB102 trial, as the company has submitted the IND application to the China FDA.
Vectura Group has reached a royalty cap on net sales of £9 million from selling GSK’s respiratory Ellipta products in 2016.
A newly formed biopharmaceutical company based in San Francisco, USA, has ensured funds for unlocking research of the therapeutic potential of Wnt signaling, a key for stem-cell maintenance and tissue regeneration.
U.S. President Donald Trump’s vow to roll back government regulations at least 75 percent is causing anxiety for some pharmaceutical executives that a less robust Food and Drug Administration would make it harder to secure insurance coverage for pricey new medicines.
Adocia plans to license its diabetes treatment products, especially its most advanced program BioChaperone Lispro. The company’s boss said that cash position of €58 million will enable the company to push BioChaperone Lispro into phase 3 clinical trial.
“The rapid roll-out of our nationwide ambulatory clinic model, and our significant new participation in the Georgian pharmaceuticals market will continue to create further business development and cost efficiency opportunities over the next few years,” said the group’s CEO Nikoloz Gamkrelidze.
Pharmapack Europe – organised by UBM EMEA – closed its 2017 edition, marking 20 years of its presence, as a major European event for pharmaceutical packaging and drug delivery devices. The top trends that emerged from the two-day event included: patient centricity, traceability, innovation, compliance and adherence.
As a part of Clintec’s – a privately-owned full-service Clinical Research Organisation (CRO) – 20th anninversary and reaching certain milestones after another year of growth, Clintec on Wednesday launched its new brand identity reflected in their newly created website.